Vision

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

Retrieved on: 
Friday, April 5, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Diagnosis, Pterygium, Disease, Eye, Conjunctiva, Safety, Physician, ASCRS, Air conditioning, Conjunctivitis, Tavarua, Tearing, Contact, Dry, Volunteering, Wind, Efficacy, Ophthalmology, Pollen, Chronic, Irritation, Pharmacokinetics, Vision, HCP, Recurrence, Pharma, Food

“Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.

Key Points: 
  • “Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.
  • As ophthalmologists, we need to listen closely to our patients and coordinate with optometrists to fully understand the impact of pterygium.
  • More information about this trial is available here: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium .
  • The survey was designed with multiple-choice questions, rating questions and open-ended questions.2

Pantheon Vision Secures a Second Tranche of $1.8 Million to Advance Bioengineered Corneal Implants

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Optical, Health, Medical Devices, KLI, Opacity (optics), Vision, Paratriathlon, FDA, Developing country, Food

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI).

Key Points: 
  • Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI).
  • This comes on the heels of a previous $2.5 million investment from last year, also from KLI, bringing the total funding to $4.3 million.
  • The funds will be used to advance Pantheon Vision’s development of bioengineered corneal implants to reduce reliance on donated corneal tissue.
  • “The additional funding from KLI positions Pantheon Vision to advance our bioengineered corneal implants to treat corneal blindness,” said John Sheets, President and CEO, Pantheon Vision.

Mojo Vision Appoints Dr. Achin Bhowmik to the Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Semiconductor, Hardware, Audio, Video, Consumer Electronics, Technology, Intel, INTC, Communication, Bhowmick, Oculus Quest, Perception, RGB, Research, Artificial intelligence, 3D, USB On-The-Go, University, Electricity, IEEE, Society, Nobel Prize, Electronics, Mojo, Vision, National Captioning Institute, GlobalFoundries, Engineering, Management

Mojo Vision, the high-performance micro-LED company, today announced the appointment of Dr. Achin Bhowmik to its board of directors.

Key Points: 
  • Mojo Vision, the high-performance micro-LED company, today announced the appointment of Dr. Achin Bhowmik to its board of directors.
  • With Bhowmik’s appointment, Mojo Vision is tapping 23 years of industry experience in perceptual computing, display, and semiconductor business.
  • “Mojo Vision is a pioneering display technology company, consistently breaking new ground in micro-LED advancements, including its recent achievement of single-panel RGB.
  • “Adding Dr. Bhowmik to our board brings Mojo that much closer to the commercialization of our high-performance micro-LED technology,” said Drew Perkins, chairman of the board of directors and co-founder.

United States Augmented and Virtual Reality Headset Analysis Report 2024: Market to Surpass $25 Billion by 2033 - Current and Future Impact Assessment - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Hardware, Electronic Games, Consumer Electronics, Technology, Entertainment, Immersion, Growth, VR, Country, Communication, Virtual reality, Health, Augmented reality, Application, Education, Meta, Health care, Meta Quest Pro, Investment, Vision, Escapism, Video game

The "U.S. Augmented and Virtual Reality Headset Market - A Country Analysis: Focus on Application, Product, and Country - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Augmented and Virtual Reality Headset Market - A Country Analysis: Focus on Application, Product, and Country - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. augmented and virtual reality headset market is projected to reach $25.492 billion by 2033 from $1.08 billion in 2023, growing at a CAGR of 36.45% during the forecast period 2024-2033.
  • Virtual Reality (VR) Headset to Hold the Largest Share in the U.S. Augmented and Virtual Reality Headset Market (by Type)
    Virtual reality (VR) headsets are favored for their immersive gaming, entertainment, and educational uses.
  • Standalone Headset to Lead the U.S. Augmented and Virtual Reality Headset Market (by Product Type)
    Standalone headsets lead the U.S. market, offering wireless, all-in-one experiences without requiring external devices.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Altria to Significantly Enhance Cash Returns to Shareholders Through Expanded Share Repurchase Program in Connection with Pricing of Offering of Anheuser-Busch InBev Stock; Raises 2024 Full-Year Earnings Guidance

Retrieved on: 
Thursday, March 14, 2024
Tobacco, Retail, Wine & Spirits, Health, Uncertainty, Climate change, European Economic Area, Growth, Gross metropolitan product, Exercise, MSA, EPS, Risk, Accounting, Law enforcement, Food and Drug Administration, Climate, ASR, History, Sale, Acquisition, ANB, Private sector, ADS, AB InBev, Euronext, Artificial intelligence, Investment, Annual report, Heated tobacco product, NPM, GAAP, Vision, Income tax, Information, Pandemic, Privacy, Food, Share repurchase, Security (finance)

In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.

Key Points: 
  • In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.
  • Our Board of Directors (Board) has authorized the expanded program, which we expect to complete by December 31, 2024.
  • Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.
  • As part of the expanded share repurchase program, we expect to enter into an estimated $2.4 billion accelerated share repurchase (ASR) program.

GroupBy Delivers AI-First Search Strategies for Retailers to Win at Shoptalk 2024

Retrieved on: 
Tuesday, March 12, 2024
Technology, Specialty, Electronic Commerce, Communications, Search Engine Optimization, Catalog, Search Engine Marketing, Digital Marketing, Retail, Software, Artificial Intelligence, Cloud, E-commerce, Taste, Software as a service, Shop Talk, AI, B2C, Human, Gossage, Vision, Online shopping

GroupBy Inc. , a SaaS-based B2C and B2B eCommerce search and product discovery technology leader, will attend Shoptalk 2024 in Las Vegas from March 17 to 20.

Key Points: 
  • GroupBy Inc. , a SaaS-based B2C and B2B eCommerce search and product discovery technology leader, will attend Shoptalk 2024 in Las Vegas from March 17 to 20.
  • Sessions will take place on Monday, March 18, at 10:30 a.m. PT and Tuesday, March 19, at 3:30 p.m. PT.
  • The Future of Retail Search: GroupBy's Vision and Strategy to Unlocking eCommerce Growth—Revolutionize eCommerce through AI-first search and discovery solutions.
  • GroupBy is leading the next-gen AI revolution with its Search and Product Discovery Platform powered by Google Cloud Vertex AI Search for Retail.

Pigment announces $145 million series D led by ICONIQ Growth

Retrieved on: 
Thursday, April 4, 2024
Keolis, Venture round, BearingPoint, HR, Organization, Vision, Growth, EVP, Trust, General partnership, SAN, Slalom, Niccolò de' Niccoli, ICONIQ, Investment, KAYAK, Datadog, Corporate development, IVP

ICONIQ Growth who spearheaded Pigment's Series C last year also led the Series D round, with participation from Sandberg Bernthal Venture Partners, IVP, Meritech, Greenoaks and Felix Capital.

Key Points: 
  • ICONIQ Growth who spearheaded Pigment's Series C last year also led the Series D round, with participation from Sandberg Bernthal Venture Partners, IVP, Meritech, Greenoaks and Felix Capital.
  • With the majority of the company's revenue now coming from North America, the capital will be used to expand Pigment's in-market support and accelerate product development
    SAN FRANCISCO, April 4, 2024 /PRNewswire/ -- Pigment today announced a $145 million Series D funding round, led by ICONIQ Growth, who also spearheaded Pigment's Series C investment close to a year ago.
  • The funding follows a successful year for Pigment as the company tripled its annual recurring revenue, and doubled its customer base globally.
  • "We are exceptionally confident that Pigment is successfully addressing a clear and very large need in the market," said Matt Jacobson, General Partner, ICONIQ Growth.

Pigment announces $145 million series D led by ICONIQ Growth

Retrieved on: 
Thursday, April 4, 2024
Keolis, Venture round, BearingPoint, HR, Organization, Vision, Growth, EVP, Trust, General partnership, SAN, Slalom, Niccolò de' Niccoli, ICONIQ, Investment, KAYAK, Datadog, Corporate development, IVP

ICONIQ Growth who spearheaded Pigment's Series C last year also led the Series D round, with participation from Sandberg Bernthal Venture Partners, IVP, Meritech, Greenoaks and Felix Capital.

Key Points: 
  • ICONIQ Growth who spearheaded Pigment's Series C last year also led the Series D round, with participation from Sandberg Bernthal Venture Partners, IVP, Meritech, Greenoaks and Felix Capital.
  • With the majority of the company's revenue now coming from North America, the capital will be used to expand Pigment's in-market support and accelerate product development
    SAN FRANCISCO, April 4, 2024 /PRNewswire/ -- Pigment today announced a $145 million Series D funding round, led by ICONIQ Growth, who also spearheaded Pigment's Series C investment close to a year ago.
  • The funding follows a successful year for Pigment as the company tripled its annual recurring revenue, and doubled its customer base globally.
  • "We are exceptionally confident that Pigment is successfully addressing a clear and very large need in the market," said Matt Jacobson, General Partner, ICONIQ Growth.

Former UnitedHealthcare Vision CEO John Ryan Joins Eyesafe as Senior Advisor

Retrieved on: 
Thursday, April 4, 2024
Health, Growth, UnitedHealth Group, Electronics, Insurance, Senior advisor, Vision, Information Age, Management

As the former CEO of UnitedHealthcare Vision, Ryan brings over three decades of executive leadership, insights, and a track record of growth.

Key Points: 
  • As the former CEO of UnitedHealthcare Vision, Ryan brings over three decades of executive leadership, insights, and a track record of growth.
  • As a Senior Advisor, John Ryan will support expansion of Eyesafe's digital wellness solutions into healthcare.
  • As a Senior Advisor for Eyesafe, John will leverage his expertise to support the company's expansion into the insurance, employer, and health and wellness sectors.
  • "We are thrilled to have John join our Senior Advisory Board," said Justin Barrett, CEO of Eyesafe.